

CITATION REPORT

List of articles citing

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

DOI: 10.1186/s12943-018-0801-5
Molecular Cancer, 2018, 17, 36.

Source: <https://exaly.com/paper-pdf/68830516/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
207	Comparative Methylome Analysis Reveals Perturbation of Host Epigenome in Chestnut Blight Fungus by a Hypovirus. 2018 , 9, 1026		8
206	Predicting Kinase Inhibitor Resistance: Physics-Based and Data-Driven Approaches. 2019 , 5, 1468-1474		15
205	Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field. 2019 , 9, 588-596		22
204	Roles of exosomes in metastatic colorectal cancer. 2019 , 317, C869-C880		16
203	Role of protein kinase CK2 in antitumor drug resistance. 2019 , 38, 287		40
202	Catalytic Hydrolysis of Phosphate Monoester by Supramolecular Complexes Formed by the Self-Assembly of a Hydrophobic Bis(Zn-cyclen) Complex, Copper, and Barbitol Units That Are Functionalized with Amino Acids in a Two-Phase Solvent System. 2019 , 10,		3
201	Emerging and Novel Treatments for Pituitary Tumors. 2019 , 8,		15
200	Determination of serum imatinib and its metabolite in patients chronic myeloid leukemia. 2019 , 497, 120-124		3
199	Tapping the therapeutic potential of protein tyrosine phosphatase 4A with small molecule inhibitors. 2019 , 29, 2008-2015		5
198	Toward Explainable Anticancer Compound Sensitivity Prediction via Multimodal Attention-Based Convolutional Encoders. 2019 , 16, 4797-4806		43
197	The emergence of drug resistance to targeted cancer therapies: Clinical evidence. 2019 , 47, 100646		48
196	Discovery and structure-activity relationship of plastoquinone analogs as anticancer agents against chronic myelogenous leukemia cells. 2019 , 352, e1900170		16
195	The Microenvironment of Pituitary Tumors-Biological and Therapeutic Implications. 2019 , 11,		25
194	Regulation of mitotic spindle orientation by phosphorylation of end binding protein 1. 2019 , 384, 111618		6
193	Silver nanoparticles alter epithelial basement membrane integrity, cell adhesion molecule expression, and TGF- β secretion. 2019 , 21, 102070		3
192	Pediatric Cardio-Oncology: Development of Cancer Treatment-Related Cardiotoxicity and the Therapeutic Approach to Affected Patients. 2019 , 20, 56		8
191	Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer. 2019 , 50, 89-100		18

190	Identification and characterization of two novel oncogenic mTOR mutations. 2019 , 38, 5211-5226	15
189	Exploring receptor tyrosine kinases-inhibitors in Cancer treatments. 2019 , 20,	21
188	Cardiovascular Toxicities in Pediatric Cancer Survivors. 2019 , 37, 533-544	12
187	MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia. 2019 , 9, 18630	7
186	New anthra[2,3-b]furancarboxamides: A role of positioning of the carboxamide moiety in antitumor properties. 2019 , 165, 31-45	18
185	Designing of benzothiazole derivatives as promising EGFR tyrosine kinase inhibitors: a pharmacoinformatics study. 2020 , 38, 1365-1374	5
184	Optimization of pyrrolizine-based Schiff bases with 4-thiazolidinone motif: Design, synthesis and investigation of cytotoxicity and anti-inflammatory potency. 2020 , 185, 111780	24
183	Diarylamides in anticancer drug discovery: A review of pre-clinical and clinical investigations. 2020 , 188, 112029	3
182	Association between copy-number alteration of +20q, -14q and -18p and cross-sensitivity to tyrosine kinase inhibitors in clear-cell renal cell carcinoma. 2020 , 20, 482	2
181	Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?. 2020 , 10, 1642	23
180	Synthesis and cytotoxic activity of novel 4-amino-5-cyano-2-sulfonylpyrimidines. 2020 , 30, 604-606	1
179	Sunitinib-induced oxidative imbalance and retinotoxic effects in rats. 2020 , 257, 118072	4
178	Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib. 2020 , 28, 963-970	4
177	Challenges and Therapeutic Opportunities of Autophagy in Cancer Therapy. 2020 , 12,	16
176	Arterial Thrombotic Complications of Tyrosine Kinase Inhibitors. 2021 , 41, 3-10	3
175	Design, synthesis and antitumor activity of icotinib derivatives. 2020 , 105, 104421	5
174	Past, Present, and Future of Anticancer Nanomedicine. 2020 , 15, 5719-5743	13
173	Mechanism of Vascular Toxicity in Rats Subjected to Treatment with a Tyrosine Kinase Inhibitor. 2020 , 8,	2

172	The Role of Tyrosine Kinases as a Critical Prognostic Parameter and Its Targeted Therapies in Ewing Sarcoma. 2020 , 8, 613	5
171	Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). 2020 , 13, 143	61
170	The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination. 2020 , 10, 10141-10153	20
169	A kinase inhibitor screen identifies signaling pathways regulating mucosal growth during otitis media. 2020 , 15, e0235634	0
168	Invadopodia: clearing the way for cancer cell invasion. 2020 , 8, 902	12
167	Reproducible and Characterized Method for Ponatinib Encapsulation into Biomimetic Lipid Nanoparticles as a Platform for Multi-Tyrosine Kinase-Targeted Therapy.. 2020 , 3, 6737-6745	9
166	Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management. 2020 , 12,	3
165	Nanohydroxyapatite-Mediated Imatinib Delivery for Specific Anticancer Applications. 2020 , 25,	2
164	Modulation of oxidative stress/antioxidative defence in human serum treated by four different tyrosine kinase inhibitors. 2020 , 31, 942-949	4
163	Phenylpyrazalopyrimidines as Tyrosine Kinase Inhibitors: Synthesis, Antiproliferative Activity, and Molecular Simulations. 2020 , 25,	6
162	Targeting of peptide-binding receptors on cancer cells with peptide-drug conjugates. 2020 , 112, e24171	12
161	Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer. 2020 , 20, 413	1
160	Design, Synthesis, Antitumor Activity and Molecular Docking Study of Novel 5-Deazaalloxazine Analogs. 2020 , 25,	2
159	The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas. 2020 , 26, 4947-4957	11
158	Hypoxia-Induced Aquaporin-3 Changes Hepatocellular Carcinoma Cell Sensitivity to Sorafenib by Activating the PI3K/Akt Signaling Pathway. 2020 , 12, 4321-4333	3
157	Reprogramming of Mesothelial-Mesenchymal Transition in Chronic Peritoneal Diseases by Estrogen Receptor Modulation and TGF- β Inhibition. 2020 , 21,	4
156	Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer. 2020 , 36, 101510	16
155	Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma. 2020 , 12, 3741-3749	7

154	Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome. 2020 , 19, 1534735420928493	14
153	Association between serum HER2/ErbB2 levels and coronary artery disease: a case-control study. 2020 , 18, 124	2
152	Mimicry of Short Linear Motifs by Bacterial Pathogens: A Drugging Opportunity. 2020 , 45, 526-544	15
151	Theoretical Studies into the Spectral Characteristics, Biological Activity, and Photovoltaic Cell Efficiency of Four New Polycyclic Aromatic Chalcones. 2020 , 1-15	2
150	Synthesis and biological evaluation of heterocyclic bis-aryl amides as novel Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors. 2020 , 30, 127170	6
149	Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF- κ B signaling pathways. 2020 , 28, 509-518	8
148	A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis. 2021 , 496, 84-92	4
147	Epoxyquinomopsins A and B from endophytic fungus Phomopsis sp. and their activity against tyrosine kinase. 2021 , 75, 217-222	5
146	Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: Synthesis and antitumor activity of novel pyrazoline derivatives. 2021 , 354, e2000351	1
145	Tuning Local Hydration Enables a Deeper Understanding of Protein-Ligand Binding: The PP1-Src Kinase Case. 2021 , 12, 49-58	3
144	Imatinib-induced pancreatic hypertrophy in patients with gastrointestinal stromal tumor: Association with overall survival. 2021 , 21, 246-252	1
143	Experimental and Computational Evaluation of Chloranilic Acid as an Universal Chromogenic Reagent for the Development of a Novel 96-Microwell Spectrophotometric Assay for Tyrosine Kinase Inhibitors. 2021 , 26,	2
142	Targeting leukemia stem cells in T-cell acute lymphoblastic leukemia (T-ALL). 2021 , 161-197	
141	Prognostic and immunological role of Fam20C in pan-cancer. 2021 , 41,	7
140	Therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALK + ALCL. 2021 , 141-159	
139	Binding of tyrosine kinase inhibitor to epidermal growth factor receptor: surface-enhanced infrared absorption microscopy reveals subtle protein secondary structure variations. 2021 , 13, 7667-7677	1
138	Tyrosine kinase inhibitor resistance: a case report on chronic myeloid leukemia and Gilbert's syndrome. 2021 , 5, 1	
137	Nanomedicine of tyrosine kinase inhibitors. 2021 , 11, 1546-1567	8

136	Design and Synthesis of Supramolecular Phosphatases Formed from a Bis(Zn ²⁺ -Cyclen) Complex, Barbitol-Crown-K ⁺ Conjugate and Cu ²⁺ for the Catalytic Hydrolysis of Phosphate Monoester. 2021 , 2021, 1213-1223	2
135	Paroxetine-Overview of the Molecular Mechanisms of Action. 2021 , 22,	4
134	Relapse of pathological angiogenesis: functional role of the basement membrane and potential treatment strategies. 2021 , 53, 189-201	8
133	A newly identified small molecular compound acts as a protein kinase inhibitor to suppress metastasis of colorectal cancer. 2021 , 107, 104625	2
132	Exogenous bacterial DnaK increases protein kinases activity in human cancer cell lines. 2021 , 19, 60	2
131	Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19. 2021 , 5, 913-925	4
130	A Mechanistic Overview of Taste Bud Maintenance and Impairment in Cancer Therapies. 2021 , 46,	4
129	The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications. 2021 , 13,	4
128	Novel Regulatory Factors and Small-Molecule Inhibitors of FGFR4 in Cancer. 2021 , 12, 633453	0
127	Thymoquinone, as a Novel Therapeutic Candidate of Cancers. 2021 , 14,	11
126	Hybrid Drugs-A Strategy for Overcoming Anticancer Drug Resistance?. 2021 , 26,	11
125	Anti-Angiogenic Properties of Ginsenoside Rg3 Epimers: In Vitro Assessment of Single and Combination Treatments. 2021 , 13,	4
124	Spectrophotometric and computational investigations of charge transfer complexes of chloranilic acid with tyrosine kinase inhibitors and application to development of novel universal 96-microwell assay for their determination in pharmaceutical formulations. 2021 , 252, 119482	5
123	Medulloblastoma recurrence and metastatic spread are independent of colony-stimulating factor 1 receptor signaling and macrophage survival. 2021 , 153, 225-237	3
122	The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death. 2021 , 112, 2442-2453	1
121	Store-Operated Calcium Channels as Drug Target in Gastroesophageal Cancers. 2021 , 12, 668730	5
120	Modulation of Src Kinase Activity by Selective Substrate Recognition with Pseudopeptidic Cages. 2021 , 27, 9542-9549	3
119	Synthesis and anticancer activity of novel 2-alkylthio-4-amino-5-(thiazol-2-yl)pyrimidines. 2021 , 51, 2521-2527	0

118	Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma. 2021 , 14,	2
117	Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia. 2021 , 12, 696960	6
116	Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis-New insight and futuristic vision. 2021 , 180, 739-752	4
115	Recent advances in pharmacological diversification of Src family kinase inhibitors. 2021 , 22,	1
114	Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer. 2021 , 14,	7
113	Advances of Targeted Therapy for Hepatocellular Carcinoma. 2021 , 11, 719896	5
112	AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer. 2021 , 12, 660313	1
111	Autocrine GMCSF Signaling Contributes to Growth of HER2 Breast Leptomeningeal Carcinomatosis. 2021 , 81, 4723-4735	2
110	The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015-2020. 2021 , 113, 105011	11
109	Kahweol Induces Apoptosis in Hepatocellular Carcinoma Cells by Inhibiting the Src/mTOR/STAT3 Signaling Pathway. 2021 , 22,	0
108	The multifaceted roles of mitochondria at the crossroads of cell life and death in cancer. 2021 , 176, 203-221	7
107	Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy. 2021 , 40, 279	4
106	Landscape of extracellular vesicles in the tumour microenvironment: Interactions with stromal cells and with non-cell components, and impacts on metabolic reprogramming, horizontal transfer of neoplastic traits, and the emergence of therapeutic resistance. 2021 , 74, 24-44	10
105	Osteosarcoma in Children: Not Only Chemotherapy. 2021 , 14,	4
104	Aggressive pituitary tumours and pituitary carcinomas. 2021 , 17, 671-684	15
103	Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers. 2021 , 116, 105325	0
102	Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. 2021 , 22,	5
101	Anticancer Drug-induced Thyroid Dysfunction. 2020 , 16, 32-39	7

100	WD Repeat Domain 5 Promotes Invasion, Metastasis and Tumor Growth in Glioma Through Up-Regulated Zinc Finger E-Box Binding Homeobox 1 Expression. 2020 , 12, 3223-3235	4
99	Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect. 2019 , 20, 1180-1202	9
98	Targeting Oncoimmune Drivers of Cancer Metastasis. 2021 , 13,	8
97	The Interactions of Nintedanib and Oral Anticoagulants-Molecular Mechanisms and Clinical Implications. 2020 , 22,	5
96	Evaluation of Different Concentrations of Imatinib on the Viability of : An Study. 2019 , 8, 61	2
95	Highly sensitive CuZnO-Fe ₃ O ₄ /rGO modified glassy carbon electrode for the electrochemical determination of acetaminophen, tyrosine and codeine in human blood plasma and urine. 2021 , 902, 115768	0
94	Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer.. 2020 , 3, 171-178	1
93	Analysis of NIS Plasma Membrane Interactors Discloses Key Regulation by a SRC/RAC1/PAK1/PIP5K/EZRIN Pathway with Potential Implications for Radioiodine Re-Sensitization Therapy in Thyroid Cancer. 2021 , 13,	0
92	Key genes and drug delivery systems to improve the efficiency of chemotherapy. 2021 , 4, 163-191	1
91	Infectious Complications of Biological Agents. 2020 , 131-163	
90	The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology-When and Why?. 2021 , 22,	2
89	CYP2C8 Suppress Proliferation, Migration, Invasion and Sorafenib Resistance of Hepatocellular Carcinoma via PI3K/Akt/p27 Axis. 2021 , 8, 1323-1338	2
88	Pyrrolo[2,1-f][1,2,4]triazine: a promising fused heterocycle to target kinases in cancer therapy. 2021 , 1-25	1
87	Protein Tyrosine Phosphatases: Mechanisms in Cancer. 2021 , 22,	2
86	Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer. 2021 , 12, 772510	7
85	Therapeutic approach and outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors: An SFCE retrospective study. 2021 , 69, e29441	1
84	Research on Kinases and Peripheral Nerve Injury Repair. 2021 , 11, 99-108	
83	A narrative review of systemic treatment options for hepatocellular carcinoma: state of the art review.. 2022 , 13, 426-437	0

82	Targeting the RT loop of Src SH3 in Platelets Prevents Thrombosis without Compromising Hemostasis.. 2022 , e2103228	2
81	New Imatinib Derivatives with Antiproliferative Activity against A549 and K562 Cancer Cells.. 2022 , 27,	2
80	Coconut Carbon Dots: Progressive Large-Scale Synthesis, Detailed Biological Activities and Smart Sensing Aptitudes towards Tyrosine.. 2022 , 12,	2
79	Recent Advances in the Chemistry and Therapeutic Evaluation of Naturally Occurring and Synthetic Withanolides.. 2022 , 27,	2
78	Current State of Pediatric Cardio-Oncology: A Review.. 2022 , 9,	0
77	Kinome-Wide Profiling Identifies Human WNK3 as a Target of Cajanin Stilbene Acid from (L.) Millsp.. 2022 , 23,	0
76	Kinase inhibitors involved in the regulation of autophagy: Molecular concepts and clinical implications.. 2022 ,	1
75	In-Silico Screening of Novel Synthesized Thienopyrimidines Targeting Fms Related Receptor Tyrosine Kinase-3 and Their In-Vitro Biological Evaluation.. 2022 , 15,	3
74	Proteomics in uveal melanoma.. 2022 ,	0
73	Recent progress of research on anti-tumor agents using benzimidazole as the structure unit.. 2022 ,	0
72	Development and validation of an UPLC-MS/MS method for simultaneous determination of fifteen targeted anti-cancer drugs in human plasma and its application in therapeutic drug monitoring.. 2021 , 212, 114517	1
71	A New Antitumor Direction: Tumor-Specific Endothelial Cells.. 2021 , 11, 756334	1
70	Torsades de pointes in patients with cancer. 2022 , 285-301	
69	APOE Is a Prognostic Biomarker and Correlates with Immune Infiltrates in Papillary Thyroid Carcinoma.. 2022 , 13, 1652-1663	0
68	Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer.. 2022 , 14,	0
67	Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook.. 2022 , 9, 233-263	3
66	Resistance Mechanisms in Pediatric B-Cell Acute Lymphoblastic Leukemia.. 2022 , 23,	1
65	Regulation of the Tec family of non-receptor tyrosine kinases in cardiovascular disease.. 2022 , 8, 119	0

64	Glycyrrhetic Acid Nanoparticles combined with Ferrotherapy for Improved Cancer Immunotherapy.. 2022 ,	5
63	Incidence and risk factors of drug-induced liver injury.. 2022 ,	0
62	Anlotinib inhibits the proliferation, migration and invasion, and induces apoptosis of breast cancer cells by downregulating TFAP2C.. 2022 , 23, 46	0
61	Chronic myeloid leukemia stem cells: targeting therapeutic implications.. 2021 , 12, 603	0
60	Analysis to determine the effect of mutations on binding to small chemical molecules.. 2022 , 2240003	
59	Recent Advances in Treatment Options for Childhood Acute Lymphoblastic Leukemia.. 2022 , 14,	7
58	Image_1.JPEG. 2018 ,	
57	Image_2.JPEG. 2018 ,	
56	Image_3.JPEG. 2018 ,	
55	Image_4.JPEG. 2018 ,	
54	Image_5.JPEG. 2018 ,	
53	Table_1.XLSX. 2018 ,	
52	New kinase and HDAC hybrid inhibitors: recent advances and perspectives.. 2022 , 14, 745-766	
51	Novel Thienyl-Based Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma. 2022 , 12, 738	0
50	Trends of receptor tyrosine kinase researches based on bibliometric analysis. 2022 , 19,	
49	LuxS in Lactobacillus plantarum SS-128 Improves the Texture of Refrigerated Litopenaeus vannamei: Mechanism Exploration Using a Proteomics Approach. 2022 , 13,	0
48	Cell Surface Markers and Their Targeted Drugs in Breast Cancer. 2022 , 23,	
47	Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia. 2022 , 27, 3220	0

46	Importance of Tyrosine Phosphorylation in Hormone-Regulated Plant Growth and Development. 2022 , 23, 6603	0
45	The Clinical Relevance of Hypothyroidism in Patients with Solid Non-Thyroid Cancer: A Tantalizing Conundrum. 2022 , 11, 3417	0
44	Coiled-coil heterodimer-based recruitment of an exonuclease to CRISPR/Cas for enhanced gene editing. 2022 , 13,	0
43	Glycosylation and its research progress in endometrial cancer.	0
42	C2-functionalized imidazo[1,2-a]pyridine: Synthesis and medicinal relevance. 1-20	0
41	Cancer Biomarkers: A Long and Tortuous Journey. 2022 , 563-580	
40	Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders. 2022 ,	0
39	The continuum of care of anticancer treatment-induced hypothyroidism in patients with solid non thyroid tumors: time for an intimate collaboration between oncologists and endocrinologists.	
38	Optimizing the Sunitinib for cardio-toxicity and thyro-toxicity by scaffold hopping approach. 2022 , 10,	5
37	Origin and Therapies of Osteosarcoma. 2022 , 14, 3503	0
36	Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives. 2022 , 14, 1784	
35	Anticancer potential of mebendazole against chronic myeloid leukemia: in silico and in vitro studies revealed new insights about the mechanism of action. 13,	1
34	Frequency and Severity of Hypothyroidism During TKI Therapy in the Pediatric and Young Adult Population. Publish Ahead of Print,	
33	Colon Cancer Pharmacogenetics: A Narrative Review. 2022 , 10, 95	0
32	Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp. 13,	0
31	The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature.	
30	Review on recent development of quinoline for anticancer activities. 2022 , 15, 104168	2
29	Polypharmacology in Clinical ApplicationsAnticancer Polypharmacology. 2022 , 73-132	0

28	Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. 2022 , 7,	1
27	Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies. 13,	2
26	Thiosemicarbazones and selected tyrosine kinase inhibitors synergize in pediatric solid tumors: NDRG1 upregulation and impaired prosurvival signaling in neuroblastoma cells. 13,	0
25	Activation of CD44/PAK1/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer. 2022 , 6,	0
24	Development and Validation of 96-Microwell-Based Spectrophotometric and High-Performance Liquid Chromatography with Fluorescence Detection Methods with High Throughput for Quantitation of Duvelisib and Seliciclib in Their Bulk Forms and Capsules. 2022 , 12, 10624	0
23	SOD2 confers anlotinib resistance via regulation of mitochondrial damage in OSCC.	1
22	Liver Fibrosis, Liver Cancer, and Advances in Therapeutic Approaches. 2022 , 2, 372-386	0
21	Molecular mechanisms underlying the role of HLA-DQ in systemic immune activation in severe aplastic anemia. 2023 , 98, 102708	0
20	Renal adverse reactions of tyrosine kinase inhibitors in the treatment of tumours: A Bayesian network meta-analysis. 13,	0
19	Screening assays for tyrosine kinase inhibitors:A review. 2022 , 115166	0
18	Design, synthesis and evaluation of novel Se-alkylated pyrazoles and their cyclized analogs as potential anticancer agents. 2023 , 1276, 134670	0
17	Tyrosine kinase inhibitor-loaded biomimetic nanoparticles as a treatment for osteosarcoma. 2022 , 13,	0
16	Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma. 2022 , 8,	0
15	Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review. 13,	0
14	Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with β -Substituent Electrophiles Targeting Cysteine.	0
13	Challenges and future of HER2-positive gastric cancer therapy. 13,	0
12	The immune microenvironment in somatotropinomas: from biology to personalized and target therapy.	0
11	A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol. 2023 , 22, 153303382311523	0

- 10 The Antiangiogenic and Antitumor Effects of Scoparasin B in Non-Small-Cell Lung Cancer. ○
- 9 Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia. **2023**, ○
- 8 Spectrophotometric Investigations of Charge Transfer Complexes of Tyrosine Kinase Inhibitors with Iodine as a Electron Acceptor: Application to Development of Universal High-Throughput Microwell Assay for Their Determination in Pharmaceutical Formulations. **2023**, 59, 775 ○
- 7 Tyrosine kinases in nodal peripheral T-cell lymphomas. 13, ○
- 6 Mass spectrometry analysis of phosphotyrosine-containing proteins. ○
- 5 Multicenter real-world experience of the clinical efficacy and tolerance of pazopanib in high-risk pediatric solid tumors (PazoPed). 1-16 ○
- 4 Molecular and functional imaging in cancer-targeted therapy: current applications and future directions. **2023**, 8, ○
- 3 Medicinal chemistry perspective of pyrido[2,3-d]pyrimidines as anticancer agents. **2023**, 13, 6872-6908 ○
- 2 Anticancer Activity of Sunitinib Analogues in Human Pancreatic Cancer Cell Cultures under Normoxia and Hypoxia. **2023**, 24, 5422 ○
- 1 Treatment failure shortcomings, possible causes and upcoming phyto-optimism in oral cancer. 4-27 ○